Nov 12, 2024 / 01:30PM GMT
Operator
Good afternoon and welcome to an Oncolytics byte third quarter, 2024 conference call.
All participants are in a listen-only mode. There will be a question and answer session at the end of this call. Please be advised that this call is being recorded at the company's request.
I would now like to turn the call over to John Patton, Director of Investor Relations and Communication. Please go ahead.
Jon Patton - Oncolytics Biotech Inc - Director of Investor Relations and Communication
Thank you operator and thank you all for joining us. After remarks from company management, we will open the call for Q&A as a reminder, various remarks made during this call contain certain forward-looking statements relating to the company's business prospects and the development and commercialization of Peller rep including statements regarding the company's mission strategy and milestones, the company's belief as to the potential and mechanism of action of Peller rep as a cancer therapeutic. Our potential registrational opportunities with plar rep and our
Q3 2024 Oncolytics Biotech Inc Earnings Call Transcript
Nov 12, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers